1. Home
  2. ICON vs AZTR Comparison

ICON vs AZTR Comparison

Compare ICON & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Icon Energy Corp.

ICON

Icon Energy Corp.

HOLD

Current Price

$0.66

Market Cap

4.7M

Sector

N/A

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.32

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICON
AZTR
Founded
2023
2014
Country
Greece
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
4.2M
IPO Year
2024
2023

Fundamental Metrics

Financial Performance
Metric
ICON
AZTR
Price
$0.66
$0.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.50
$4.00
AVG Volume (30 Days)
1.8M
314.3K
Earning Date
04-02-2026
11-12-2025
Dividend Yield
1297.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,449,000.00
N/A
Revenue This Year
$94.05
N/A
Revenue Next Year
$18.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
96.44
N/A
52 Week Low
$0.69
$0.30
52 Week High
$106.60
$4.33

Technical Indicators

Market Signals
Indicator
ICON
AZTR
Relative Strength Index (RSI) 23.16 35.03
Support Level $0.72 $0.34
Resistance Level $0.83 $0.39
Average True Range (ATR) 0.08 0.03
MACD 0.02 0.01
Stochastic Oscillator 0.00 3.37

Price Performance

Historical Comparison
ICON
AZTR

About ICON Icon Energy Corp.

Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: